Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Shorter recall period for the thyroid-related patient-reported outcome measure ThyPRO did not change the accuracy as evaluated by repeated momentary measurements

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Effects of supplemental vitamin D on muscle performance and quality of life in Graves' disease. A randomized clinical trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Thyroid peroxidase antibodies and prospective live birth rate: A cohort study of women with recurrent pregnancy loss

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Thoughts on the Japanese and American Perspectives on Thyroid Storm

    Research output: Contribution to journalReviewResearchpeer-review

  4. Muscle Performance and Postural Stability Are Reduced in Patients with Newly Diagnosed Graves' Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effects of supplemental vitamin D on muscle performance and quality of life in Graves' disease. A randomized clinical trial

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background: The thyroid-related patient-reported outcome measure ThyPRO has become the gold standard for measuring thyroid-related quality of life and uses a 4-week recall period. The impact of the length of recall is unresolved. To minimize recall bias, the US Food and Drug Administration has argued in favor of short recall periods or measures describing current states. We investigated whether a 1-week recall version of ThyPRO was less prone to recall bias than the original ThyPRO, using averaged momentary ThyPRO measurements as the hypothesized true mean of patients' symptoms. Methods: Patients newly diagnosed with thyrotoxicosis were included (N = 122). During a 28-day study period, participants answered momentary questions three times daily via a smartphone, weekly retrospective surveys with a 1-week recall period, and the original survey with a 4-week recall period on day 28. Twelve ThyPRO items from four multi-item scales were used. Mean momentary ratings for each scale were compared with recall ratings of 1- and 4-week periods, respectively. Results: The mean momentary ratings were highly correlated with retrospective ratings and remained rather constant when altering the reporting period from four weeks to one week. We found consistently lower scores (i.e., better thyroid-related quality of life) on momentary ratings compared with retrospective ratings. The mean differences between momentary ratings and retrospective ratings were similar for both recall periods. The original 4-week ThyPRO accurately summarized the mean of all 1-week ThyPROs. Conclusions: Shortening the recall period of ThyPRO from four weeks to one week was not associated with less recall bias within this subset of items. Nor did 1-week recall seem to compromise the accuracy of ThyPRO. Thus, either version of ThyPRO can be used in future studies.

Original languageEnglish
JournalThyroid : official journal of the American Thyroid Association
Volume30
Issue number2
Pages (from-to)185-191
Number of pages7
ISSN1050-7256
DOIs
Publication statusPublished - Feb 2020

ID: 59035876